title: Reply to Soman et al and Frippiat et al.
authors.forename: Matthew E
authors.initials: ME
authors.lastname: Falagas
authors.forename: Giannoula S
authors.initials: GS
authors.lastname: Tansarli
authors.forename: Kazuro
authors.initials: K
authors.lastname: Ikawa
authors.forename: Konstantinos Z
authors.initials: KZ
authors.lastname: Vardakas
mesh_terms: D000900:Anti-Bacterial Agents / Q000008:administration & dosage* / Q000627:therapeutic use*; D001424:Bacterial Infections / Q000188:drug therapy*; D015780:Carbapenems / Q000008:administration & dosage*; D005260:Female; D006801:Humans; D008297:Male; D010397:Penicillanic Acid / Q000031:analogs & derivatives*; D010878:Piperacillin / Q000008:administration & dosage*; D018805:Sepsis / Q000188:drug therapy*; D047090:beta-Lactams / Q000627:therapeutic use*
chemical_list: D000900:Anti-Bacterial Agents; D015780:Carbapenems; D047090:beta-Lactams; D010397:Penicillanic Acid; D010878:Piperacillin